Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA: Rucaparib and Nivolumab in Ovarian Cancer
NCT03522246Phase 3Active, not recruiting
- Sponsor
- pharma&
- Start
- May 2018
- Primary completion
- May 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of rucaparib, nivolumab in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by pharma&. Started May 2018; status: active, not recruiting.
02
Drugs
rucaparibnivolumab
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03522246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522246.